194 related articles for article (PubMed ID: 37879679)
1. Efficacy and safety of therapeutic HPV vaccines to treat CIN 2/CIN 3 lesions: a systematic review and meta-analysis of phase II/III clinical trials.
Ibrahim Khalil A; Zhang L; Muwonge R; Sauvaget C; Basu P
BMJ Open; 2023 Oct; 13(10):e069616. PubMed ID: 37879679
[TBL] [Abstract][Full Text] [Related]
2. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Role of human papillomavirus (HPV) vaccination on HPV infection and recurrence of HPV related disease after local surgical treatment: systematic review and meta-analysis.
Kechagias KS; Kalliala I; Bowden SJ; Athanasiou A; Paraskevaidi M; Paraskevaidis E; Dillner J; Nieminen P; Strander B; Sasieni P; Veroniki AA; Kyrgiou M
BMJ; 2022 Aug; 378():e070135. PubMed ID: 35922074
[TBL] [Abstract][Full Text] [Related]
5. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy and immunogenicity of therapeutic vaccines in the treatment of patients with high-grade cervical intraepithelial neoplasia associated with human papillomavirus: a systematic review protocol.
Gonçalves CA; Lopes-Júnior LC; Nampo FK; Zilly A; Mayer PCM; Pereira-da-Silva G
BMJ Open; 2019 Jul; 9(7):e026975. PubMed ID: 31320349
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Human Papillomavirus Vaccine to Reduce Recurrent Cervical Dysplasia in Unvaccinated Women: A Systematic Review and Meta-analysis.
Lichter K; Krause D; Xu J; Tsai SHL; Hage C; Weston E; Eke A; Levinson K
Obstet Gynecol; 2020 May; 135(5):1070-1083. PubMed ID: 32282601
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
[TBL] [Abstract][Full Text] [Related]
9. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): Impact of human papillomavirus (HPV) test.
van der Heijden E; Lopes AD; Bryant A; Bekkers R; Galaal K
Cochrane Database Syst Rev; 2015 Jan; 1(1):CD010757. PubMed ID: 25562623
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial.
van de Laar RLO; Hofhuis W; Duijnhoven RG; Polinder S; Melchers WJG; van Kemenade FJ; Bekkers RLM; Van Beekhuizen HJ
BMC Cancer; 2020 Jun; 20(1):539. PubMed ID: 32517663
[TBL] [Abstract][Full Text] [Related]
11. Human papillomavirus vaccination in women undergoing excisional treatment for cervical intraepithelial neoplasia and subsequent risk of recurrence: A systematic review and meta-analysis.
Eriksen DO; Jensen PT; Schroll JB; Hammer A
Acta Obstet Gynecol Scand; 2022 Jun; 101(6):597-607. PubMed ID: 35470865
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials.
Rambout L; Hopkins L; Hutton B; Fergusson D
CMAJ; 2007 Aug; 177(5):469-79. PubMed ID: 17671238
[TBL] [Abstract][Full Text] [Related]
13. HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysis.
Mac Eochagain C; Power R; Parker I; Brennan D
J Gynecol Oncol; 2022 May; 33(3):e24. PubMed ID: 35128855
[TBL] [Abstract][Full Text] [Related]
14. Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
Grabosch SM; Shariff OM; Helm CW
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD004121. PubMed ID: 29431861
[TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.
Harper DM; Nieminen P; Donders G; Einstein MH; Garcia F; Huh WK; Stoler MH; Glavini K; Attley G; Limacher JM; Bastien B; Calleja E
Gynecol Oncol; 2019 Jun; 153(3):521-529. PubMed ID: 30955915
[TBL] [Abstract][Full Text] [Related]
16. Cervical Intraepithelial Neoplasia 3 (Cervical Intraepithelial Neoplasia 3/High-Grade Squamous Intraepithelial Lesion) in Human Papillomavirus-Vaccinated Women-Results From a Tertiary Referral Center.
Domröse CM; Wieland U; Pilch H; Einzmann T; Schömig-Markiefka B; Mallmann P; Silling S; Mallmann MR
J Low Genit Tract Dis; 2022 Apr; 26(2):122-126. PubMed ID: 35019900
[TBL] [Abstract][Full Text] [Related]
17. Advances in therapeutic vaccines for treating human papillomavirus-related cervical intraepithelial neoplasia.
Barra F; Della Corte L; Noberasco G; Foreste V; Riemma G; Di Filippo C; Bifulco G; Orsi A; Icardi G; Ferrero S
J Obstet Gynaecol Res; 2020 Jul; 46(7):989-1006. PubMed ID: 32390320
[TBL] [Abstract][Full Text] [Related]
18. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
19. Non-steroidal anti-inflammatory agents to induce regression and prevent the progression of cervical intraepithelial neoplasia.
Grabosch SM; Shariff OM; Wulff JL; Helm CW
Cochrane Database Syst Rev; 2014 Apr; 2014(4):CD004121. PubMed ID: 24715225
[TBL] [Abstract][Full Text] [Related]
20. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions.
Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Dillner J; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan J; Maansson R; Lu S; Vuocolo S; Hesley TM; Saah A; Barr E; Haupt RM
Cancer Prev Res (Phila); 2009 Oct; 2(10):868-78. PubMed ID: 19789295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
